1
|
Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions. Int J Mol Sci 2023; 24:ijms24043886. [PMID: 36835299 PMCID: PMC9961679 DOI: 10.3390/ijms24043886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 01/24/2023] [Accepted: 02/14/2023] [Indexed: 02/17/2023] Open
Abstract
As the backbone of oncological treatments, systemic chemotherapy is still one of the main pawns in cancer care, alone or in combination with newer targeted agents. All chemotherapy agents can be associated with a type of adverse event called an infusion reaction, which can be characterized as unpredictable, non-dose related, and unexplained by the cytotoxic profile of the drug. For some of these events, a certain immunological mechanism can be identified by blood or skin testing. In this case, we can speak of true hypersensitivity reactions that occur as a response to an antigen/allergen. The current work summarizes the main antineoplastic therapy agents and their susceptibility to induce hypersensitivity reactions and also includes a review of clinical presentation, diagnostic methods in hypersensitivity reactions, and perspectives to overcome these negative events in the treatment of patients suffering from various types of cancer.
Collapse
|
2
|
Stockton W, Lam F, Nguyen T, Nguyen T, Kirov I. Six-step etoposide desensitization protocol: A pediatric, adolescent, and young adult case series. Pediatr Blood Cancer 2021; 68:e28795. [PMID: 33155419 DOI: 10.1002/pbc.28795] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 09/18/2020] [Accepted: 10/13/2020] [Indexed: 11/08/2022]
Abstract
Etoposide administration can be complicated by hypersensitivity reactions. Desensitization may provide a strategy to prevent hypersensitivity recurrence. One challenge with desensitization is regimen complexity. This case series describes 12 pediatric, adolescent, and young adult patients who received a simplified six-step etoposide desensitization protocol. This protocol contains 50% fewer titration steps compared with previously described protocols and eliminates infusion rate changes during titration. Simplified titration may minimize risk of error during administration and improve safety. This protocol was tolerated by 92% of patients. Given increasing frequency and duration of drug shortages, a simplified desensitization protocol provides a valuable treatment option.
Collapse
Affiliation(s)
- Winifred Stockton
- Department of Pharmacy, Children's Hospital of Orange County, Orange, California
| | - Fionna Lam
- Department of Pharmacy, Children's Hospital of Orange County, Orange, California
| | - Theresa Nguyen
- Department of Pharmacy, Children's Hospital of Orange County, Orange, California
| | - Tran Nguyen
- Department of Pharmacy, Children's Hospital of Orange County, Orange, California
| | - Ivan Kirov
- Division of Oncology, Hyundai Cancer Institute, Children's Hospital of Orange County, Orange, California
| |
Collapse
|
3
|
Yuan D, Chen Y, Yang Z, Li G, Wu M, Jiang J, Li D, Yu Q. SPOP attenuates migration and invasion of choriocarcinoma cells by promoting DHX9 degradation. Am J Cancer Res 2020; 10:2428-2445. [PMID: 32905556 PMCID: PMC7471363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 07/14/2020] [Indexed: 06/11/2023] Open
Abstract
Speckle-type POZ protein (SPOP), a novel cancer- associated protein, was previously reported to function as a tumor suppressor or promoter in different malignant tumors. This research aims to investigate the biological functions and underlying molecular mechanisms of SPOP in choriocarcinoma. Our analysis of patient tissues and cell lines showed significantly decreased SPOP expression and highly expressed Nuclear DNA helicase II and RNA helicase A (DHX9), both of them are mainly located into the nucleus. Induction or depletion of endogenous SPOP with a lentivirus-based system correspondingly suppressed or promoted migration and invasion of choriocarcinoma cells. Mechanistically, we found that SPOP bound to DHX9 and induced the ubiquitination and degradation of DHX9 by recognizing a typical SPOP-binding motif in DHX9. SPOP-DHX9 interaction was demonstrated to play a critical role in regulating migration and invasion abilities of choriocarcinoma cells, the promotion of mobility ability in knocking down SPOP was partly counteracted by transfection with siRNA against DHX9. Taken together, our results suggest that SPOP suppresses migration and invasion of choriocarcinoma by promoting the ubiquitination and subsequent degradation of DHX9, which identifies the SPOP-DHX9 interaction may serve as a potential therapeutic target against choriocarcinoma.
Collapse
Affiliation(s)
- Dong Yuan
- Department of Gynecology, The Second Affiliated Hospital of Chongqing Medical UniversityChongqing 400010, P. R. China
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Yiyu Chen
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Zhu Yang
- Department of Gynecology, The Second Affiliated Hospital of Chongqing Medical UniversityChongqing 400010, P. R. China
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Gang Li
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Mingjun Wu
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Jinyue Jiang
- Department of Respiratory, The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Dan Li
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| | - Qiubo Yu
- Molecular Medical Laboratory, Institute of Life Sciences, Chongqing Medical UniversityChongqing 400016, P. R. China
| |
Collapse
|
4
|
Martinez N, Miyasaki A, Roh L, Koole W, Fernandez KS. A pediatric desensitization protocol for etoposide. Am J Health Syst Pharm 2020; 77:277-281. [DOI: 10.1093/ajhp/zxz311] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Purpose
The implementation of a pediatric desensitization protocol specific to etoposide in an adolescent with Hodgkin lymphoma is described.
Summary
Etoposide is part of many chemotherapy regimens used to treat malignancies in children and adults, and it is also part of the backbone of many regimens used in clinical trials. Etoposide is known to produce hypersensitivity reactions during administration. Substitution with etoposide phosphate, which has less potential for hypersensitivity reactions, is used in place of etoposide after severe hypersensitivity reactions. Etoposide desensitization protocols (EDPs) have been reported in adult patients.
Conclusion
The implementation of an etoposide desensitization protocol for pediatric patients is safe and helpful to prevent the elimination of etoposide from treatment protocols. The use of an EDP allowed the patient to remain on clinical trial and complete the prescribed treatment.
Collapse
Affiliation(s)
- Nicole Martinez
- Department of Pharmacy, Valley Children’s Hospital, Cancer and Blood Disorders Center, Madera, CA
| | - Ashley Miyasaki
- Department of Pharmacy, Valley Children’s Hospital, Cancer and Blood Disorders Center, Madera, CA
| | - Lucy Roh
- Department of Pharmacy, Valley Children’s Hospital, Cancer and Blood Disorders Center, Madera, CA
| | - William Koole
- Department of Pharmacy, Valley Children’s Hospital, Cancer and Blood Disorders Center, Madera, CA
| | - Karen S Fernandez
- Department of Pharmacy, Valley Children’s Hospital, Cancer and Blood Disorders Center, Madera, CA
| |
Collapse
|
5
|
Stockton WM, Nguyen T, Zhang L, Dowling TC. Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies. J Oncol Pharm Pract 2019; 26:397-405. [DOI: 10.1177/1078155219858390] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Introduction Etoposide is critical in treating pediatric cancers, although hypersensitivity can be severe and treatment-limiting. Reported rates of hypersensitivity range from 2% to 51%. Hypersensitivity data for etoposide phosphate, a newer product, are lacking. The primary objective of this study was to assess etoposide and etoposide phosphate hypersensitivity incidence. Secondary objectives included evaluation of potential risk factors for hypersensitivity and strategies to prevent recurrence. Methods This retrospective cohort study evaluated pediatric patients who received initial etoposide phosphate or etoposide dose between August 2012 and July 2017. The primary outcome was documentation of hypersensitivity within four months of initial dose. Potential risk factors evaluated included age, allergies, dose, infusion rate, infusion concentration, and premedication. Results Of 246 patients, hypersensitivity reactions occurred in five of 54 patients (9.3%) who received etoposide phosphate and 52 of 192 patients (27.1%) who received etoposide ( p = 0.0061). For etoposide, the mean initial infusion rate was 64.6 ± 40.9 mg/m2/h for patients with hypersensitivity and 49.5 ± 33.4 mg/m2/h without hypersensitivity ( p = 0.0886). Etoposide phosphate rate was not associated with hypersensitivity. Recurrent hypersensitivity occurred in one of nine patients (11.1%) who received etoposide desensitization and one of 38 patients (2.6%) who changed formulation to etoposide phosphate. Conclusions Etoposide was associated with more hypersensitivity than etoposide phosphate in pediatric patients. Etoposide hypersensitivity was associated with higher infusion rates, but not etoposide phosphate. Differences in hypersensitivity incidence and infusion rate influence indicate a formulation-effect. Etoposide hypersensitivity recurrence may be prevented by changing to etoposide phosphate formulation. During etoposide phosphate shortages, etoposide desensitization may prevent recurrent hypersensitivity.
Collapse
Affiliation(s)
- Winifred M Stockton
- Children's Hospital of Orange County, Department of Pharmacy, Orange, CA, USA
| | - Theresa Nguyen
- Children's Hospital of Orange County, Department of Pharmacy, Orange, CA, USA
| | - Lishi Zhang
- Biostatistics, Institute for Clinical and Translational Science, University of California, Irvine, CA, USA
| | - Thomas C Dowling
- Ferris State University, College of Pharmacy, Big Rapids, MI, USA
| |
Collapse
|
6
|
Brooks JP, Azmy V, Thompson A, Luon D, Prozora SD, Price C, Hsu FI. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity. J Oncol Pharm Pract 2019; 26:228-231. [DOI: 10.1177/1078155219836478] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Background Hypersensitivity reactions to etoposide have been reported and patients have been safely transitioned to etoposide phosphate for continued therapy. However, the safety and efficacy of substituting etoposide phosphate for etoposide has not been well established in pediatric orthopedic malignancies. The aim of this study is to determine whether etoposide phosphate can be substituted for etoposide in pediatric orthopedic malignancies. Methods A chart review of pediatric patients who developed hypersensitivity reactions to etoposide while being treated for orthopedic malignancies was performed at a large academic medical center. Three patients were identified, two with Ewing sarcoma and one with an osteosarcoma. All three patients experienced hypersensitivity reactions to their first doses of etoposide and were switched to etoposide phosphate for further therapy. Results After premedication, all three patients tolerated full doses of etoposide phosphate without a graded dose challenge or desensitization. Two of the patients were premedicated with diphenhydramine alone, while the third received diphenhydramine and dexamethasone. Conclusions Etoposide phosphate is a potentially safe alternative for pediatric patients with orthopedic malignancies who experience etoposide hypersensitivity. However, caution is needed as there are cases of etoposide phosphate hypersensitivity.
Collapse
Affiliation(s)
- Joel P Brooks
- School of Medicine, Department of Internal Medicine, Section of Allergy and Clinical Immunology, Yale University, New Haven, CT, USA
| | - Veronica Azmy
- School of Medicine, Department of Internal Medicine, Section of Allergy and Clinical Immunology, Yale University, New Haven, CT, USA
| | - Alison Thompson
- School of Medicine, Department of Internal Medicine, Section of Allergy and Clinical Immunology, Yale University, New Haven, CT, USA
| | - Darren Luon
- Department of Pharmacy, Section of Oncology, Yale New Haven Hospital, New Haven, CT, USA
| | - Stephanie D Prozora
- School of Medicine, Department of Pediatrics, Section of Hematology and Oncology, Yale University, New Haven, CT, USA
| | - Christina Price
- School of Medicine, Department of Internal Medicine, Section of Allergy and Clinical Immunology, Yale University, New Haven, CT, USA
| | - F Ida Hsu
- School of Medicine, Department of Internal Medicine, Section of Allergy and Clinical Immunology, Yale University, New Haven, CT, USA
| |
Collapse
|
7
|
Myricetin suppresses invasion and promotes cell death in human placental choriocarcinoma cells through induction of oxidative stress. Cancer Lett 2017; 399:10-19. [PMID: 28428076 DOI: 10.1016/j.canlet.2017.04.014] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Revised: 03/24/2017] [Accepted: 04/07/2017] [Indexed: 11/23/2022]
Abstract
Myricetin is a bioactive compound found in a variety of vegetables and fruits, and its anti-cancer effects are well known. In this study, we confirmed that myricetin reduced proliferation of two choriocarcinoma cell lines (JAR and JEG-3) and also promoted apoptosis and regulated cell cycle progression in a dose-dependent manner in JAR and JEG-3 cells. In addition, we found that invasive and pro-angiogenic properties of malignant JAR and JEG-3 trophoblast cells were attenuated by myricetin treatment via MAPK and PI3K/AKT signaling pathways. In addition, we found that ROS production, lipid peroxidation, glutathione depletion, and loss of mitochondrial membrane potentials were enhanced in JAR and JEG-3 cells treated with myricetin. Moreover, myricetin augmented cytosolic Ca2+ release from the endoplasmic reticulum associated with modulation of ER stress in JAR and JEG-3 cells. Our results also revealed that myricetin had synergistic antiproliferative effects with current chemotherapeutics, etoposide and cisplatin, on choriocarcinoma cells. Collectively, results of the present study provide strong evidence for the potential of myricetin to be an effective therapeutic for the prevention of human placental choriocarcinomas.
Collapse
|
8
|
Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma. Bone Marrow Transplant 2016; 52:455-456. [DOI: 10.1038/bmt.2016.288] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
9
|
Leguay Z, Bourneau-Martin D, Pellier I, Le Louet H, Drablier G, Lagarce L, Lainé-Cessac P. Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate. Pediatr Blood Cancer 2016; 63:571. [PMID: 26468691 DOI: 10.1002/pbc.25797] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Accepted: 09/18/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Zoé Leguay
- Pharmacovigilance Centre, Department of Pharmacology, University Hospital, Angers Cedex, France
| | | | - Isabelle Pellier
- Pediatric Haematology-Oncology-Immunology Centre, Department of Paediatrics, University Hospital, Angers Cedex, France
| | - Hervé Le Louet
- Pharmacovigilance Centre, University Hospital, Créteil Cedex, France
| | - Guillaume Drablier
- Pharmacovigilance Centre, Department of Pharmacology, University Hospital, Angers Cedex, France
| | - Laurence Lagarce
- Pharmacovigilance Centre, Department of Pharmacology, University Hospital, Angers Cedex, France
| | - Pascale Lainé-Cessac
- Pharmacovigilance Centre, Department of Pharmacology, University Hospital, Angers Cedex, France
| |
Collapse
|
10
|
Cyclophosphamide, Hydroxyurea, Actinomycin D, Methotrexate, and Vincristine in the Treatment of Gestational Trophoblastic Neoplasia. Int J Gynecol Cancer 2015; 25:498-503. [DOI: 10.1097/igc.0000000000000383] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
11
|
Lee JS, Hyun SH, Lee JS, Kim IS. The Correlation between the Blood Sugar and Allergy of the Trauma Patient. KOREAN JOURNAL OF CLINICAL LABORATORY SCIENCE 2014. [DOI: 10.15324/kjcls.2014.46.1.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- Jeong Soo Lee
- Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 301-746, Korea
- Department of Senior Healthcare, BK21 plus program, Graduated School, Eulji University, Daejeon 301-746, Korea
| | - Sung Hee Hyun
- Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 301-746, Korea
- Department of Senior Healthcare, BK21 plus program, Graduated School, Eulji University, Daejeon 301-746, Korea
| | - Ji-Sook Lee
- Department of Clinical Laboratory Science, Wonkwang Health Science University, Iksan 570-750, Korea
| | - In Sik Kim
- Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 301-746, Korea
- Department of Senior Healthcare, BK21 plus program, Graduated School, Eulji University, Daejeon 301-746, Korea
| |
Collapse
|